Drugs / TRV120027
TRV120027
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04419610 | Oct 2020 → May 2021 | COVID-19 | Imperial College London | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01444872 | Aug 2011 → May 2012 | heart failure, kidney disorder | Trevena Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01187836 | Dec 2010 → Mar 2012 | heart failure | Trevena Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01966601 | Dec 2013 → Mar 2016 | heart failure | Trevena Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04924660 | Jul 2021 → Oct 2023 | COVID-19 | Sean Collins | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRV120027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01187836 ↗ |
| Known as | Formerly known as TRV120027 | “Formerly known as TRV120027” NCT01966601 ↗ |
| Known as | Sar-val-tyr-ile-his-pro-d-ala-oh | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297447 ↗ |
| Known as | TRV-027 | “2 investigational RAS agents, TXA-127 (synthetic angiotensin [1-7]) and TRV-027 (an angiotensin II type 1 receptor-biased ligand)” PMID 37039791 ↗ Apr 2023 |
| Action | Activate | “TRV027 is a similar peptide to Ang(1-7) but is a much more potent biased agonist at AT1R than Ang(1-7)” NCT04419610 ↗ |
| Action | Inhibit | “Type-1 angiotensin II receptor antagonist” CHEMBL4297447 ↗ |
| Modality | Peptide | “An investigational peptide biased agonist of the AT1 receptor.” NCT04924660 ↗ |
| Route | Intravenous | “TRV120027 (or a placebo) intravenous infusion will be given to people with heart failure.” NCT01187836 ↗ |
| Target | AGTR1 | “Type-1 angiotensin II receptor antagonist” CHEMBL4297447 ↗ |